ASH 2013
Dr. Jennifer Brown Discusses the New Data on Obinutuzumab (GA-101 or Gazyva)
Dr. Claire Dearden Discusses CLL Treatment in the Elderly
Dr. Furman: Idelalisib in Fragile CLL (Chronic LymphocyticLeukemia) Patients
Dr. Neil Kay on Why We Need a CLL (chronic lymphocytic leukemic) Expert and on Clonal Evolution
Dr. John Pagel Discusses Radio-Immune Therapy (RIT) in Chronic Lymphocytic Leukemia (CLL)
Dr. Jeff Sharman Discusses FCR versus BR in Front Line CLL
Dr. Wiestner Discusses Why Therapy in CLL Needs to be Individualized
iwCLL 2013
Dr. Jan Burger Discusses More Details on How the New Targets Therapies (TKIs) work in CLL
Dr. Jan Burger Discusses the Role of the Micro-environment in CLL: Part 1
Dr. Byrd Discusses If and When to Stop and the Long Term Use of Ibrutinib
Dr. Byrd Discusses 17 p deletion with Ibutinib
Dr. John Byrd Discusses the Role of Novel Therapies versus Standard Chemo-Immunotherapy
Part 2: Dr. George Calin Explains more about the Critical Role of micro-RNA in CLL
Interview with Dr. Castro on the Biology of CLL
Prof Hallek Discusses a Focused Role of Chemo-Immunotherapy
Dr. Michael Hallek Discusses Clinical Trials in Germany versus the USA and BR versus FCR
Dr. Jeff Sharman Discusses Richter’s Transformation in CLL
Dr. Jeff Sharman Discusses Two Issues: 17p deletion and Residual Disease in CLL
Dr. Jeff Sharman Outlines Options if You Need Treatment NOW
Dr. Jeff Sharman Discusses Why We Feels so Lousy with Cancer
Dr. Jeff Sharman Gets Down to Discussing How He Treats Patients with High Risk Disease
Dr. Jeff Sharman Discusses the Practicalities of the New Prognostic Factors
Pharmacogenetics and Dr. Jeff Sharman Discusses New Prognostic Factors
ASCO 2013
Abstract: ABT-199 in Relapsed and Refractory CLL Patients
Press Release and Abstract about Idelalisib (CAL-101 or GS1101) in Treatment Naive CLL Patients
Dr. Jeff Sharman on Mantle Cell Lymphoma (MCL) and Coffee and Road Map.
Dr. Sharman on The Biology of CLL being Cracked with a Therapeutic Renaissance Underway
Dr. Wierda on Prognostic Factors in CLL (Chronic Lymphocytic Leukemia)
Dr. Wierda Discusses Immune Therapies in CLL
ASH 2012
Dr. John Byrd thanks the patients
Dr. John Byrd Discusses Possible Complications of the New Therapies and the New Trials
Dr. Richard Furman Discusses What is Known and What Isn’t About the New Treatments in Trial
Dr. Rick Furman Discussed the Very Early Experiences with Idelalisib and Ibrutinib
Dr. Tom Kipps on Genetics, Epigenetics, and Targeted Therapy
Dr. Tom Kipps Explains BCR, Chemokines, and the Power of Blocker Drugs
Dr. Pagel discusses transplants for CLL and the Role of Radioimmunotherapy
Dr. John M. Pagel Part 1 Game changing medications including ABT-199, Ibrutinib, and GS-1101 for CLL
Dr Jeff Sharman interviewed about the new treatments in CLL
Dr. David P Steensma: Myelodysplastic Syndrome with a Focus on Secondary MDS in CLL
Dr. Wierda and Practical Advice on CAR-T Trials
Dr. Bill Wierda on CAR-T Therapies and “Off the Shelf” T-Cells
ABSTRACTS
Experimental Ibrutinib Promotes High Response Rate in Leukemia
The Absolute Latest on Ibrutinib. Press Release from ASH 2012